Onco Actu du 26 novembre 2015

	2.7 Etiologie - Obésité
How exactly does obesity cause cancer? Three leading theories [Cancer Research UK] There’s not a shadow of doubt that obesity is linked to cancer, but unravelling the biological reasons why is proving complicated.
	4.9 Dép., diag. & prono. - Sein
Ecological technique to find cancer-tracking immune cells predicts breast cancer survival [The Institute of Cancer Research] The researchers from The Institute of Cancer Research, London, analysed sections of biopsied tumour samples from 1002 breast cancer patients using powerful imaging and statistical software to quantify the spatial interactions of immune cells and cancer cells.
	5.2 Pharma
Presage Nabs Cancer Rx To Test In Its Drug Cocktail Injection System [Xconomy] The company said Tuesday it has licensed voruciclib from the Indian firm Piramal Enterprises. It’s a type of drug known as a cyclin-dependent kinase inhibitor; earlier this year, Pfizer’s palbociclib (Ibrance) was the first of the type to be approved in the U.S.
Pfizer’s Plan to Leave U.S. Unsettles Drug Lobbyists [NY Times] “This Pfizer thing is humongous, and I think it could change the course of history for the entire industry,” one of the industry’s top lobbyists said in an interview. “Pfizer shot us all in the collective foot.”
	5.3 Traitements - FDA, EMA,...
Cancer Gene Therapies: FDA Officials Highlight Regulatory Approaches [RAPS] Although FDA has yet to approve a gene therapy to treat cancer, the authors note that about two-thirds of gene therapy clinical trials are for cancer treatments.
	5.3.4 Traitements - AMM (FDA, EMA)
Roche receives EU approval of Cotellic for use in combination with Zelboraf in advanced melanoma [Roche ] Today’s EU approval is based primarily on results of the Phase III coBRIM study, which showed that people with previously untreated BRAF V600 mutation-positive advanced melanoma who were being treated with the MEK inhibitor Cotellic in combination with Zelboraf lived a median of one year (12.3 months) without their disease worsening or death (progression-free survival; PFS) compared to 7.2 months with Zelboraf alone.
EU approves Roche's Cotellic in combo therapy against skin cancer [Reuters] Roche is counting on Cotellic to help it revive flagging sales of five-year-old Zelboraf, which dropped 25 percent during the first nine months of 2015.
	5.5 ASCO
2016 Genitourinary Cancers Symposium Press Program to Feature Research Advances in Prostate and Kidney Cancers [ASCO] The following studies will be featured during the presscast: -A subgroup analysis from a phase III trial comparing cabozantinib to everolimus in patients with advanced kidney cancer (Abstract 499). -A large study evaluating the association between regular aspirin use and the risk of lethal prostate cancer (Abstract 306). -A study investigating circulating tumor cell characteristics to predict resistance to androgen deprivation therapies in patients with advanced prostate cancer (Abstract 163).
	6.1 Observation
‘Angelina Jolie effect’ sees increase in double mastectomy rates among high-risk women at UK centre [Cancer Research UK] "We now need more research into better ways of preventing breast cancer in high-risk women so that they could potentially avoid surgery.”
Children’s cancer death rates drop by a quarter in 10 years [Cancer Research UK] The latest figures show death rates for all cancers in children aged 14 and under have fallen from around 30 deaths per million in 2004 to almost 23 deaths per million today.
	6.10 Politiques
Spending Review 2015: will it affect research and cancer? [Cancer Research UK] The Spending review has been a mixed picture for cancer, with welcome news for the Cancer Strategy and frustration over public health.